Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Fetal bovine acellular dermal matrix for the closure of diabetic foot ulcers: a prospective randomised controlled trial

Autor: Robert J Snyder, John C Lantis, Alexander M. Reyzelman, Lawrence A. Lavery, Carl C Van Gils, Joseph M. Caporusso, Felix Sigal, Shawn Cazzell, Dean Vayser

Publikováno v: Journal of Wound Care. 30:S18-S27

Aim: The purpose of this clinical trial was to evaluate the safety and efficacy of a fetal bovine acellular dermal matrix (FBADM) plus standard of care (SOC) for treating hard-to-heal diabetic foot ulcers (DFUs). Method: A prospective, multi-centre,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c5ec5ea6629e82b2507bd4bc84718fe
https://doi.org/10.12968/jowc.2021.30.sup7.s18

Zobrazit plný text záznamu

The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study

Autor: C van Gils, E. Fakra, P. Guillon, C. Arteaga Duarte

Publikováno v: L'Encéphale. 45:459-467

Objectives Schizophrenia entails a considerable humanistic and economic burden. Improved treatment continuity to antipsychotic therapy is paramount to reduce the risk of relapse. The novel three-monthly paliperidone palmitate treatment (PP3M) offers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e909437dbfd930edb2291ff7fd58c5ea
https://doi.org/10.1016/j.encep.2019.03.001

Zobrazit plný text záznamu

HTA77 The Use and Acceptability of External Comparator Studies to Support Hemato-Oncology Single-Arm Trial Submissions to Health Technology Assessment Bodies

Autor: S Dijkhuis, D Patel, S Foster, A van Engen, C van Gils

Publikováno v: Value in Health. 25:S311

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d5bbd1afaa380a9dc5a111320662777
https://doi.org/10.1016/j.jval.2022.09.1537

Zobrazit plný text záznamu

P38 One Size Does Not Fit All: Calculating the Cost-Effectiveness of Multiple Indications of Pembrolizumab in the Netherlands

Autor: F Verbeek, C van Gils, R Heine, C Uyl-De Groot

Publikováno v: Value in Health. 25:S9

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e492992b1f3b1ff81f94bad7a6c70aa6
https://doi.org/10.1016/j.jval.2022.09.050

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: Results from the EPIC cohort

Autor: Sarink, D. Schock, H. Johnson, T. Chang-Claude, J. Overvad, K. Olsen, A. Tjønneland, A. Arveux, P. Fournier, A. Kvaskoff, M. Boeing, H. Karakatsani, A. Trichopoulou, A. La Vecchia, C. Masala, G. Agnoli, C. Panico, S. Tumino, R. Sacerdote, C. Van Gils, C.H. Peeters, P.H.M. Weiderpass, E. Agudo, A. Rodríguez-Barranco, M. Huerta, J.M. Ardanaz, E. Gil, L. Kaw, K.T. Schmidt, J.A. Dossus, L. His, M. Aune, D. Riboli, E. Kaaks, R. Fortner, R.T.

Background: Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::d445cd88468a4d0c0c288619e480fddd
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3087047

Zobrazit plný text záznamu

A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers

Autor: Cyaandi Dove, Jessica T. Pierce, Carl C. Van Gils, Molly C. Saunders, Charles E. Ananian, Raymond J. Otto, D. Craig Lindsey, Yadwinder S. Dhillon

Publikováno v: Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 26(3)

Randomized controlled clinical trials, the gold standard to determine treatment efficacy against control, have demonstrated advantages of skin substitutes for the treatment of chronic diabetic foot ulcers in comparison to standard of care. However, r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d08f9a1ab93423d45ceab4fb046c76f3
https://pubmed.ncbi.nlm.nih.gov/30098272

Zobrazit plný text záznamu

Cost and mortality data of a regional limb salvage and hyperbaric medicine program for Wagner Grade 3 or 4 diabetic foot ulcers

Autor: J V, Eggert, E R, Worth, C C, Van Gils

Publikováno v: Underseahyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc. 43(1)

We obtained costs and mortality data in two retrospective cohorts totaling 159 patients who have diabetes mellitus and onset of a diabetic foot ulcer (DFU). Data were collected from 2005 to 2013, with a follow-up period through September 30, 2014. A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5c82a95a0afb7b4d954887cb90cd1923
https://pubmed.ncbi.nlm.nih.gov/27000008

Zobrazit plný text záznamu

Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers

Autor: S M Gray, C J Lynch, R A Pollak, C van Gils, P S Kwon, J R Hanft, C P Semba, A Barbul, T J Breen

Publikováno v: Journal of Wound Care. 17:30-37

Objective: To assess the safety/tolerability and perform a preliminary efficacy evaluation of a multiple-dosing regimen of recombinant human vascular endothelial growth factor (VEGF165 or rhVEGF; telbermin) applied topically to chronic diabetic neuro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15ff1b66b48b378d0dbb2e3321a7d94d
https://doi.org/10.12968/jowc.2008.17.1.27917

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání